Mastocytosis Registry (of Zurich) (MastoR)
Genetic, Multiomic and Cytokine-based Mapping of Patients With Mastocytosis/Hypertryptasemia at the University Hospital of Zurich German: Mastozytose-Register: Datenerfassung Und Weiterverwendung Von Biologischem Material Von Patienten Mit Mastozytose, Welche am Universitätsspital Zürich Behandelt Werden
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Claudia Lang, MD
- Phone Number: +41442551111
- Email: claudia.lang@usz.ch
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Recruiting
- University Hospital of Zurich
-
Contact:
- Claudia Lang, MD
- Phone Number: +41442551111
- Email: claudia.lang@usz.ch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients with mastocytsis/hypertryptasemia which are treated at the university hospital of Zurich
- available informed consent
Exclusion Criteria:
- denied consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Mastocytosis
Diagnosed mastocytosis according to WHO criteria
|
|
Hypertryptasemia
Repeated elevated serum tryptase with no underlying mastocytosis or no bone marrow biopsy performed
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demographics
Time Frame: 2010-2025
|
In the registry we collect patient's demographic data e.g.
age, gender, comorbidities, smoking, preexisting atopic disease and other to look for associations to mast cell diseases.
|
2010-2025
|
|
Disease progression
Time Frame: 2010-2025
|
Patients will followed up over time to get more insight in disease progression.If there is progression detected (e.g.
cutaneous mastocytosis to systemic mastocytosis or ISM to advanced forms) those cases will be carefully looked at to identify triggering factors and biomarkers.
|
2010-2025
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BASEC 2020-01568
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.